SurModics Inc

SurModics — Merger or Acquisition (July 2021)

15 slides from SurModics's merger presentation, Jul 6, 2021

  1. Slide 1: Surmodics Expands Thrombectomy Portfolio with Acquisition of Vetex Medical Limited

    © 2021 Surmodics, Inc. CONFIDENTIAL All rights reserved. 1 Surmodics Expands Thrombectomy Portfolio with Acquisition of Vetex Medical Limited Galway, Ireland Exhibit 99.2

  2. Slide 2: Safe Harbor

    Some of the statements made in this presentation may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical or current facts, including statements about the timetable for manufacturing process validation

  3. Slide 3: Acquisition of Vetex Medical Limited

    © 2021 Surmodics, Inc. CONFIDENTIAL All rights reserved. Acquisition of Vetex Medical Limited 3 Vetex Medical Limited Founded in 2016 Private Company, based in Galway, Ireland Developed the ReVene™ Thrombectomy Catheter Medtech Innovator 2016 Semi-Finalist Intellectual Property: 4 U.S., 1 EU and 3 J

  4. Slide 4: Acquisition rationale: two cleared thrombectomy products and accelerated strategy

    With this acquisition Surmodics, now has two cleared products for both arterial and venous thrombosis which significantly accelerates its strategy of clinical introduction of thrombectomy devices in multiple vascular beds Groundbreaking design with compelling competitive advantages and multi-geograp

  5. Slide 5: Deal Terms

    Deal Terms $39.9 million upfront payment Up to $7 million, $3.5 million of which is guaranteed, payable upon achievement of certain new product development and regulatory milestones Transaction provides for 100% ownership of Vetex Medical Limited Deal Funding $29.9 million financed with cash on hand

  6. Slide 6: Large, Underpenetrated Market Opportunity

    © 2021 Surmodics, Inc. CONFIDENTIAL All rights reserved. 6 Large, Underpenetrated Market Opportunity ARTERIAL CLOT REMOVAL U.S. MARKET Potential for rapid growth in a high-ASP product category DVT $1.4 Billion 9% Current Penetration ASP Ranges: $2K – $7K PE $1.7 Billion 8% Current Penetration ASP Ra

  7. Slide 7: Deep vein thrombosis is a major health problem affecting over 600,000 U.S. patients per year

    © 2021 Surmodics, Inc. CONFIDENTIAL All rights reserved. Deep vein thrombosis is a major health problem affecting over 600,000 U.S. patients per year(1) Treatment algorithms that leverage conservative medical management as first-line treatment are dated relative to the current technology and treatme

  8. Slide 8: Vetex Venous Thrombectomy Solution Design Goals

    The market needs a stand-alone, easy-to-use, single session device that efficiently removes large clot volume and enables the early treatment of patients in an outpatient setting © 2021 Surmodics, Inc. CONFIDENTIAL All rights reserved. 8 Vetex Venous Thrombectomy Solution Design Goals Aimed at Gaini

  9. Slide 9: Designed to Improve Upon Current Available Technologies

    © 2021 Surmodics, Inc. CONFIDENTIAL All rights reserved. 9 Designed to Improve Upon Current Available Technologies Small footprint device accommodates guidewire positioning and management No IVC filter contraindication Smaller venotomy Dual action of wall-apposing capture basket and Archimedes remov

  10. Slide 10: Vetex Venous Thrombectomy Design Functionality

    The device’s dual action technology consists of a constant spring tension basket which provides optimal wall apposition over a range of vessel diameters to engage and collect the clot while the motor-driven Archimedes screw macerates and removes the collected clot Designed to efficiently remove mixe

  11. Slide 11: How It Works

    © 2021 Surmodics, Inc. CONFIDENTIAL All rights reserved. 11 How It Works The collection basket is expanded and maintains wall-to-wall vessel contact to engage and collect clot The Archimedes removal catheter is powered ON to feed clot into the opening for automatic removal The constant tension sprin

  12. Slide 12: Vetex Venous Thrombectomy System Features

    © 2021 Surmodics, Inc. CONFIDENTIAL All rights reserved. Vetex Venous Thrombectomy System Features 12 Venous Thrombectomy System Designed for mechanical clot removal in the peripheral vasculature Vessel sizes between 6 mm – 16 mm 10 Fr catheter system Infusion port (optional use of thrombolytics) St

  13. Slide 13: 19-Patient Clinical Evaluation with 12-month Data

    © 2021 Surmodics, Inc. CONFIDENTIAL All rights reserved. 13 19-Patient Clinical Evaluation with 12-month Data RESULTS Study Primary Performance Endpoints met in all cases (100%); No Device or thrombectomy procedure related adverse events No Thrombolytics used in 84.2% of cases during the procedure (

  14. Slide 14: Regulatory Status

    FDA Clearance received in December of 2020 CE Mark granted May 2021 Approved Indication: For mechanical de-clotting and controlled and selected infusion of physician specified fluids, including thrombolytics, in the peripheral vasculature The Vetex ReVene™ Thrombectomy Catheter currently is not indi

  15. Slide 15: Accelerates Vision and Enhances Strategic Value

    Surmodics now has two cleared products for both arterial and venous thrombosis Significantly accelerates company strategy of clinical introduction of thrombectomy devices in multiple vascular beds Groundbreaking design with compelling competitive advantages Easy-to-use, stand-alone, single session t

Surmodics — Merger or Acquisition (July 2021) on 6ix